Neurogene (NASDAQ:NGNE) CFO Christine Mikail Cvijic Sells 4,061 Shares of Stock

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 4,061 shares of the stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $34.82, for a total value of $141,404.02. Following the transaction, the chief financial officer directly owned 88,840 shares of the company’s stock, valued at approximately $3,093,408.80. This trade represents a 4.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Mikail Cvijic also recently made the following trade(s):

• On Wednesday, July 1st, Christine Mikail Cvijic sold 739 shares of Neurogene stock. The stock was sold at an average price of $34.06, for a total value of $25,170.34.
• On Wednesday, May 6th, Christine Mikail Cvijic sold 9,600 shares of Neurogene stock. The stock was sold at an average price of $31.25, for a total transaction of $300,000.00.

Neurogene Stock Up 4.3%

NGNE opened at $35.34 on Friday. The firm has a 50-day moving average price of $29.23 and a 200-day moving average price of $23.25. Neurogene Inc. has a twelve month low of $15.93 and a twelve month high of $37.27. The company has a market capitalization of $558.37 million, a price-to-earnings ratio of -7.77 and a beta of 1.68.

Neurogene (NASDAQ:NGNE) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.09). On average, sell-side analysts expect that Neurogene Inc. will post -5.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on NGNE shares. Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a research note on Tuesday, April 21st. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of Neurogene in a research note on Tuesday, June 9th. Guggenheim started coverage on shares of Neurogene in a research note on Tuesday, April 28th. They issued a “buy” rating and a $69.00 target price on the stock. UBS Group set a $70.00 price target on Neurogene in a report on Wednesday, June 3rd. Finally, Rodman & Renshaw started coverage on shares of Neurogene in a report on Wednesday, June 3rd. They issued a “buy” rating and a $70.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Neurogene has a consensus rating of “Buy” and a consensus price target of $84.83.

Hedge Funds Weigh In On Neurogene

Several large investors have recently modified their holdings of the stock. BNP Paribas Financial Markets boosted its stake in Neurogene by 89.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after purchasing an additional 978 shares in the last quarter. Daiwa Securities Group Inc. bought a new stake in Neurogene during the 4th quarter valued at about $66,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Neurogene by 17.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after buying an additional 1,059 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of Neurogene by 24.7% in the third quarter. PNC Financial Services Group Inc. now owns 5,055 shares of the company’s stock worth $88,000 after buying an additional 1,000 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Neurogene in the 4th quarter valued at approximately $165,000. Hedge funds and other institutional investors own 52.37% of the company’s stock.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.